chartexchange

BIXT
BIOXYTRAN INC
stockOTC

EODNov 16, 2026
0.0222USD-3.478%(-0.0008)24,950
Loading…
Loading…
Healthcare
Biotechnology
HQ
Newton, MA, USA
Previous Close
$0.02
Beta
-0.17
52-Week High
$0.09 2025-12-26
52-Week Low
$0.02 2026-11-11
SMA 50
$0.02
SMA 200
$0.03
Avg. Vol 10D
87,839
Avg. Vol 30D
71,164
Avg. Vol 90D
89,816
Relative Vol
0.35
177.20M
72.21M
60,031
Aug 22, 2018 · 1-for-30 (reverse)
BIXT Profile

bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

BIXT Performance
PeriodPriceDateChangeBeta
1W0.022026-11-10-4.31%-0.745
1M0.022026-10-16-4.72%-0.690
3M0.032026-08-17-15.27%-0.828
6M0.032026-05-18-32.73%-1.141
1Y0.062025-11-17-64.14%-0.172
2Y0.092024-11-18-76.04%—
5Y0.012021-11-22+85.00%-4.403
BIXT Stock Summary

BIOXYTRAN INC (OTC:BIXT) stock price today is $0.02, and today's volume is 24,950. BIXT is down 3.478% today. The 30 day average volume is 71,164. BIXT market cap is $3.93M with 177.20M shares outstanding.